RealPennies.com: (OTCBB:INIS) International Isotopes, Inc.

RealPennies.com: (OTCBB:INIS) International Isotopes, Inc.
Are you a public company looking for exposure?
Contact RealPennies.com 1-646-417-8211

For more info: http://cpwe.realpennies.com/

International Isotopes Inc. Announces Second Quarter and Six Months 2008 Financial Results
Monday August 18, 9:25 am ET
Revenue Increases 56% for the Quarter and 51% for the Six Months Gross Profit Increases 71% for 3 months; 78% for Six Months

IDAHO FALLS, Idaho, Aug. 18 - International Isotopes Inc. announces financial results for the second quarter and six-months ending June 30, 2008.
Revenue:
Revenue for the three and six-month periods ended June 30, 2008 were $1,876,042 and $3,183,980 as compared to $1,203,305 and $2,105,937 for the same periods in 2007, an increase of $672,737 and $1,078,043 or approximately 56% and 51% respectively.

Revenue From Sales of Cobalt Products:
The increase in total revenue was attributable to strong performance in the cobalt and radiochemical products business segments. Revenue from the sale of cobalt products for the six-month period ending June 30, 2008 were $1,150,044 compared to $214,040 for the same period in 2007. Revenue from the sale of cobalt products for the three-month period ending June 30, 2008 were $879,516 compared to $175,015 for the same period in 2007. This represents approximately a factor of five increase in revenue in the cobalt products segment. The increase is largely attributable to a continued increase in sales of sealed cobalt sources and teletherapy capsules to numerous customers. The sales of bulk cobalt also had a significant impact on revenue for the period. The timing of large bulk cobalt product sales during the course of the calendar year has a significant impact on period comparisons.
Excluding bulk cobalt sales, revenue for the three-month period ended June 30, 2008, were $1,387,786 as compared to $1,203,305 for the same period in 2007, which represents an increase of $184,481 or 15%. Excluding bulk cobalt product sales, revenue for the six-month period ended June 30, 2008, were $2,695,724 as compared to $2,105,937 for the same period in 2007, which represents an increase of $589,787 or 28%. Management believes that excluding sales of bulk cobalt products from the period comparisons of revenue provides useful information to investors. Historically the Company has excluded all cobalt product sales for period comparisons. However, the growth in sales of cobalt products, such as sealed sources warrants adjusting this comparison to only exclude bulk cobalt product sales revenue for the period comparisons. Please refer to the following tables for a further analysis of this measure:
Three-Month Financial Measure Reconciliation Period ended Period ended June 30, 2008 June 30, 2007 Total Revenue $1,876,042 $1,203,305 Bulk Cobalt Products Revenue $488,256 $0 Total Revenue Excluding Bulk Cobalt Products Revenues $1,387,786 $1,203,305 Six-Month Financial Measure Reconciliation Period ended Period ended June 30, 2008 June 30, 2007 Total Revenue $3,183,980 $2,105,937 Bulk Cobalt Products Revenue $488,256 $0 Total Revenue Excluding Bulk Cobalt Products Revenues $2,695,724 $2,105,937

Revenue From The Sale Of Radiochemical Products:
Revenue from the sale of radiochemical products for the three-month period ending June 30, 2008, were $349,990 compared to $284,092 for the same period in 2007. Revenues from the sale of radiochemical products for the six-month period ending June 30, 2008, were $668,398 compared to $510,006 for the same period in 2007. These represent increases in revenue of $65,898, or about 23%, and $158,392, or about 31% for the three and six-month periods respectively. Increases in the segment performance are attributable to increased sales of radiochemical iodine-131.

Revenue From The Sale of Nuclear Medicine Products:
Revenue from nuclear medicine products for the three-month period ending June 30, 2008 were $464,288 compared to $455,910 for the same period in 2007. Revenues from the sale of nuclear medicine products for the six-month period ending June 30, 2008, were $911,698 compared to $919,778 for the same period in 2007. This represents an increase in revenue of $8,378, or 1.1%, and a decrease in revenue of $8,080, or less than 1%, respectively.
Revenue From The Radiological Services Segments:
Revenue from the radiological services segment for the three-month period ending June 30, 2008 were $166,548 compared to $219,290 for the same period in 2007; a decrease of $52,742 or 24%. Revenue from radiological services segment for the six-month period ending June 30, 2008, were $412,270 compared to $366,899 for the same period in 2007. This represents an increase in revenue of $45,371 or approximately a 12% increase and is primarily attributable to increased volumes of gemstone processing that have resulted following resolution of the regulatory issues that had limited revenues in this segment during 2007.

Gross Profit:
Gross profit for the three and six-month period ended June 30, 2008, was $950,671 and $1,649,073 compared to $555,417 and $929,030 for the same periods in 2007. These represent increases of $395,254 or 71%, and $720,043, or 78%, for the three and six month periods respectively.

Operating Expense:
Operating expenses increased to $1,177,670 and $2,323,177 for the three and six-month period ended June 30, 2008 compared to $865,112 and $1,785,937 for the same periods of 2007. This represents an increase of $312,558, or 36%, and $537,240 or 30%, for the three and six-month periods respectively. However, overall operating costs declined from 85% and 72% of sales for the six and three-month periods in 2007, to 73% and 63% of sales for the same periods in 2008.
Net Loss: Our net loss for the three and six-month periods ended June 30, 2008 was $246,710 and $712,654 compared to a loss of $351,448 and $869,994 for the same periods in 2007. The reduction in loss was attributable to savings in overall cost of goods sold and operational expense as they relate directly to sales.
Steve T. Laflin, President and CEO of International Isotopes Inc. said, "Major improvements in cobalt product sales and continued increases in our radiochemicals segment have driven our improved financial performance this year. We continue to improve our gross profit performance and reduce operating cost when compared as a percentage of total revenue. In fact, much of the increase in operating expense is attributed to the addition of full time staff, subcontractors, and legal counsel necessary to support continued growth of the fluorine products division including pilot plant demonstration and efforts related to equipment acquisition, raising capital, and protecting newly developed intellectual property. All of those efforts are directed at furthering our long term goals and objectives of constructing a hybrid depleted uranium de-conversion processing and fluorine extraction facility as announced in June 2008."

International Isotopes Inc. Three Months Ended June 30 Six Months ended June 30 2007 2008 2007 2008 Sales $1,203,305 $1,876,042 $2,105,937 $3,183,980 Gross Profit $ 555,417 $ 950,671 $929,030 $1,649,073 Total Operating Expense $865,112 $1,177,670 $1,785,937 $2,323,177 Operating Other Net Net Per Common Share Weighted Ave. Shares Outstanding 238,935,747 277,122,436 229,244,222 270,055,656

About International Isotopes Inc.
International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients.

International Isotopes Inc. Safe Harbor Statement
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statement with respect to improving our financial performance, decreasing our operating expenses, and the Company's goals with respect to constructing a hybrid depleted uranium de-conversion processing and fluorine extraction facility. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in International Isotopes Inc.'s filings with the Securities and Exchange Commission at www.sec.gov, including our annual report on Form 10-KSB for the year ending December 31, 2007. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For More Information, Contact:
Steve Laflin, President and CEO
524-5300

LAST $0.77 USD

Read our full disclaimer at: http://www.realpennies.com

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on
http://www.realpennies.com/content/view/42

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

RealPennies .
Telephone: 1-646-417-8211
news /at/ realpennies.com